• Elios Therapeutics, LLC recently received FDA approval of its Investigational New Drug (IND) application and its randomized phase IIb trial planned to enroll 120 stage III and IV (resected) melanoma patients to assess the ability of a personalized vaccine to prevent recurrence.
  • Vaccine for Cancer Comes Closer to Fruition as Immunotherapy Pioneer Joins Orbis Health Solutions
  • Buddy Long, president of Perseus PCI, the advanced cancer treatment center headquartered in the Cayman Islands, has announced the appointment of Dr. Sook Yin MD as treating physician and clinic director at the company’s Cayman Islands clinic.
  • A US-based doctor and biomedical researcher who has developed a radiation and chemotherapy-free cancer treatment has opened a clinic in the Cayman Islands because, he says, the wait for the Food and Drug Administration's approval is years away.
  • Clinical trials of a cancer vaccine for patients with a specific stage of melanoma have begun at Perseus, a Cayman company that specializes in personalized cancer immunotherapeutics (PCI) that treat solid tumors.

About Orbis

Orbis Health Solutions is a biotech company located in Greenville,SC founded in 2009 by Dr. Tom Wagner. The knowledge base and intellectual property foundation of Orbis Health Solutions is molecular immunology. At the center or core of Orbis and its allied companies is a team of researchers working to develop new and improved methods to stimulate a patient’s immune system to enhance its ability to recognize and destroy disease entities with a primary focus on cancer. While therapeutic vaccines for the treatment of a wide range of malignancies have been developed and brought into clinical trials by this team, continued improvement of these present vaccines as well as development of new and different vaccine technologies is the research emphasis of Orbis scientists. This emphasis is directed in three general areas of research: 1) improvement and further development of the patented and patent pending “particle delivery” technology to directly introduce tumor and other disease antigens into the antigen presenting dendritic cells of a patient’s immune system. 2) development of effective DNA vaccines and DNA vaccine technology and 3) development of methods of enhancing the innate immune system of a patient. The specific research programs ongoing include the following:

1. Enhanced Therapeutic Vaccines: The present technology that provides the scientific

base of the Orbis Health Solutions, LLC/Perseus PCI, Ltd./Elios Therapeutics, LLC tumor vaccine effort provides a means of maximal tumor antigen presentation to the immune system through naturally functioning Dendritic Cells (DCs). The latest iterations of this technology no longer require preparation of DCs outside the patient’s body but allow for delivery of the entire tumor antigen profile of the patient into monocytes in the dermis of the patient. Using the new technology, it is no longer necessary to harvest patient blood to produce the DCs, providing significant production and distribution benefits.

2. Fundamentally Modify Dendritic Cells: The technology referenced in paragraph 1 above can also be used to fundamentally modify the DCs – generating dramatically enhanced DCs capable of stimulating a significantly more robust anti-tumor immune response. Using patented technology from Orbis Health Solutions, LLC (“Orbis”), it is possible to safely introduce not only tumor antigens but also genes constructed to express high levels of pro-inflammatory cytokines generating an even stronger “killer” T cell response. This concept not only has significant implications in cancer vaccine efficacy, but applies to vaccine delivery in any setting including infectious disease vaccines.

3. Non-personalized Cancer Vaccine: Another significant area of research and

development interest addresses cancer patients who do not have tumor tissue available. Orbis researchers believe a non-personalized vaccine may be possible using Orbis’ unique vaccine particle delivery system. This vaccine would be an “off the shelf” product that uses existing cancer cell lines to provide the antigens for the DC vaccine.

4. Switching Tumor Macrophages: Macrophages, the principal action cell of the innate

immune system, recognize tumor cells innately as foreign, infiltrate tumors to attack these tumor cells but are, by yet unknown mechanisms, switched to a phenotype cell that actually supports tumor and tumor cell growth. The genetic switch to return those macrophages to a genetic profile that would instantly destroy adjacent tumor cells is now known and the means to introduce the genetic switch to revert these cells of the innate immune system to tumor killing cells resides within the particle delivery technology of Orbis. Injecting a cancer patient with particles that would introduce this genetic switch into all or most of their macrophages would hyper-activate these innate immune cells to attack target cells and destroy them.

5. DNA vaccine: While the concept of a vaccine that consists only of a DNA molecule encoding

the antigen(s) of the vaccine has been an exciting goal for some time, DNA vaccines have been singularly unsuccessful. The main reason for their lack of success in providing effective immunization is the very low protein expression levels encoded by them. The reason for these low expression levels is the inability of the DNA to enter the nucleus of the generally non-dividing cells at the injection site. As an offshoot of our cancer vaccine studies Orbis scientists have developed a highly novel DNA vectors that can express high levels of their encoded proteins in the cytoplasm of the target cells without the necessity of entering the nucleus. Such a DNA vaccine platform has application in most all areas of vaccine technology including therapeutic cancer vaccines as well as most other prophylactic vaccines. This technology also has significant applications to stem cell therapy and CAR T cell therapies.

We have created a wholly-owned subsidiary named Perseus which acts as the treatment arm of Orbis.